). They are also inconsistent with our own findings. We genotyped rs373863828 in two NZ European sample sets and observed A-allele frequencies of 0.15% in the Screening for Pregnancy Endpoints (SCOPE) study and 0.19% in the Gout Genetics study (Table 1) . These frequencies were considerably higher than observed in the Genome Aggregation Database (P Fisher = 1 × 10 −4 and 4 × 10 −7 , respectively), consistent with the introduction of the A-allele into the NZ European population by admixture with the Māori and Pacific populations. However, the frequencies in our sample sets were tenfold lower than those reported by Berry et al. [1] and differed significantly (P Fisher < 3 × 10
), with non-overlapping 99% confidence intervals. We also genotyped two NZ Asian sample sets derived from the same studies, observing no A-allele-positive individuals in either sample set ( Table 1) .
The SCOPE European and Asian data are drawn from a similar population to that of Berry et al. We also note that the Gout Genetics and SCOPE NZ European genotypes exhibited Hardy-Weinberg equilibrium (P = 0.96 and 0.95, respectively), whereas the Berry et al. [1] European data set did not (P = 0.01). Deviation from Hardy-Weinberg equilibrium can be caused by genotyping errors [6] or, in a multi-ethnic cohort, misalignment of genotype to individuals. These possibilities require further investigation by Berry et al., which could involve the use of ancestry informative markers, before accepting their results on the biologically important CREBRF rs373863828 variant are correct or generalizable to the NZ population of children.
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